Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults
NCT03779854Phase 2Active, not recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2019
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in graft-versus-host disease (GVHD) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Feasibility achievement at 2 years, Engraftment of neutrophils by day 28 and 1 more. Started Aug 2019; status: active, not recruiting.
02
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03779854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779854.